Background and Objectives: Gestational diabetes mellitus (GDM) is characterized by insulin resistance and metabolic dysregulation, in which adipokines may be involved. We evaluated serum Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) and C1q/TNF-related protein-1 (CTRP1) in women with GDM and normal glucose tolerance and assessed their relationships with glucose–insulin homeostasis and cross-sectional discriminatory ability. Materials and Methods: This exploratory cross-sectional biomarker study with prospective obstetric follow-up included 100 pregnant women at 24–28 weeks of gestation (50 GDM and 50 controls). WISP-1, CTRP1, HOMA-IR, and GDM status were assessed during the same gestational period; therefore, the principal biomarker analyses were cross-sectional. GDM was diagnosed using the one-step 75-g oral glucose tolerance test criteria recommended by the American Diabetes Association Standards of Care 2026. WISP-1 and CTRP1 were measured by ELISA. Group comparisons, correlation analyses, ROC analyses, nested logistic regression, and bootstrap internal validation were performed. Results: WISP-1 was higher in GDM than in controls (422.80 [387.10–471.85] vs. 315.00 [288.30–351.55] pg/mL; p < 0.001), as was CTRP1 (34.13 ± 6.74 vs. 26.50 ± 5.65 ng/mL; p < 0.001). WISP-1 showed a higher apparent AUC than CTRP1 in the present cohort (0.908 vs. 0.802; DeLong p = 0.034). In the final model adjusted for maternal age and BMI, both WISP-1 (adjusted OR per 1-SD increase 7.53, 95% CI 2.95–19.21; p < 0.001) and CTRP1 (3.61, 95% CI 1.45–8.99; p = 0.006) remained associated with GDM status after adjustment for these covariates. Within GDM, the age- and BMI-adjusted association between WISP-1 and HOMA-IR remained significant (partial ρ = 0.574; p < 0.001), whereas CTRP1 was not associated with HOMA-IR. Conclusions: WISP-1 and CTRP1 were elevated in GDM, with WISP-1 showing a stronger association with HOMA-IR and a higher internally derived AUC in this cohort. These findings support further investigation of WISP-1 and CTRP1 as exploratory metabolic biomarkers associated with GDM but do not establish diagnostic or predictive utility. Independent external validation is required before any potential clinical application.
No takes yet. Share an insight, caveat, or question.
Akin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: